research

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Authors
Publication date
1 January 2017
Publisher
Digital Commons@Becker
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Digital Commons@Becker

      redirect
      oaioai:digitalcommons.wustl.edu:o...
      Last time updated on 15/06/2017